Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
This study is ongoing, but not recruiting participants.
Study NCT00006368 Information provided by National Cancer Institute (NCI)
First Received: October 4, 2000 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Lung Cancer
Lymphoma
Melanoma (Skin)
Neoplastic Syndrome
Additional conditions recognized in this trial
Adenoma, Islet Cell
Breast Neoplasms
Carcinoid Tumor
Central Nervous System Neoplasms
Gastrointestinal Neoplasms
Lung Neoplasms
Malignant Carcinoid Syndrome
Melanoma
Nervous System Neoplasms
Syndrome
More general conditions related to this trial
Adenocarcinoma
Adenoma
Breast Diseases
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Disease
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Immune System Diseases
Immunoproliferative Disorders
Lung Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Nervous System Diseases
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Pancreatic Diseases
Pancreatic Neoplasms
Pathologic Processes
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Interventions listed in this trial
yttrium Y 90-edotreotide
Additional drug interventions recognized in this trial
Octreotide
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Back to top of Main Content
